Transaction overview

HPH III Investments, LP, a private equity firm focused on the health and wellness sector, acquired Allergy Research Group LLC (ARG) from Kikkoman Corporation in July 2023. The terms of the transaction were not disclosed. ARG is a leading provider of hypoallergenic supplements to healthcare practitioners and has established itself as a significant player in this channel since its founding in 1979.

Deal structure and financing

While specific financial details are undisclosed, HPH III Investments likely utilized a combination of equity and debt financing for the acquisition. Rothschild & Co served as the sell-side advisor for Kikkoman Corporation, but no information was provided on buy-side advisors or lead banks involved in arranging the deal's financing. The transaction did not specify whether Kikkoman retained any stake in ARG post-acquisition, nor were there details regarding lock-up terms or IPO optionality.

Strategic context

HPH III Investments' acquisition of ARG aligns with its strategy to invest in middle-market companies within the natural consumer health sector, particularly those focusing on functional foods, vitamins, minerals and supplements. The deal allows HPH III to enter a high-growth healthcare practitioner channel that is expected to grow at 7% annually, making it second only to e-commerce growth according to Nutritional Business Journal. ARG's strong market position in this specialized distribution channel, combined with its commitment to product innovation and customer engagement, provides a solid foundation for future value creation.

Regulatory path

As the transaction involved parties domiciled in the United States but did not disclose specific financial details or regulatory filings, it is unclear whether HPH III Investments required approval from U.S. regulators such as the Federal Trade Commission (FTC) or Department of Justice (DOJ). Given that ARG operates primarily within a healthcare practitioner distribution channel and does not appear to have significant market overlap with competitors at this scale, antitrust scrutiny seems unlikely. However, without public disclosure on regulatory filings, definitive information about required approvals remains unavailable.